Aleix Prat

Also affiliated with Hospital Clínic de Barcelona, Universitat de Barcelona

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.649Author DataRank

Indexed papers

7in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 7 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models

UNC Libraries(2020)10.17615/43yk-w772

Top 31%

0.649DataRank

Top 31%17 citations

Qing Lai, Pavel Zuloaga, Amber M. Froehlich, Edward S. Chen, Jian Huang +24 more

Papers

Driven by 29 papers — median percentile 35. Top paper: “Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer”.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast Cancer Research(2020)10.1186/s13058-020-01354-y

N/A

3.0DataRank · unranked

148 citations

Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo +18 more

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial

European Journal of Cancer(2021)10.1016/j.ejca.2021.05.018

N/A

1.4DataRank · unranked

43 citations

Maria Vittoria Dieci, Gaia Griguolo, Federica Miglietta, Fabio Girardi, Giancarlo Bisagni +13 more

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

Nature Reviews Clinical Oncology(2024)10.1038/s41571-024-00939-2

N/A

0.852DataRank · unranked

41 citations

Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortés +3 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0.721DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

The Lancet Oncology(2020)10.1016/s1470-2045(20)30450-2

N/A

0.650DataRank · unranked

75 citations

Valentina Guarneri, Laia Paré, Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci +34 more

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models

UNC Libraries(2020)10.17615/43yk-w772

Top 31%

0.649DataRank

Top 31%17 citations

Qing Lai, Pavel Zuloaga, Amber M. Froehlich, Edward S. Chen, Jian Huang +24 more

Pregnancy After Breast Cancer in Young BRCA Carriers

JAMA(2024)10.1001/jama.2023.25463

N/A

0.614DataRank · unranked

59 citations

Eva Blondeaux, Elisa Agostinetto, Anne-Sophie Hamy, Hee Jeong Kim, Antonio Di Meglio +199 more

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

UNC Libraries(2020)10.17615/zy2g-ye61

N/A

0.449DataRank · unranked

19 citations

Christine E. Ryan, Aleix Prat, Zhanfang Guo, Matthew J. Ellis, W. Timothy Schaiff +8 more

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

ESMO Open(2024)10.1016/j.esmoop.2024.102388

N/A

0.442DataRank · unranked

18 citations

Tomás Pascual, Fara Brasó‐Maristany, Laia Paré, Olga Martínez‐Sáez, Javier Cortés +15 more

Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts

Cancer(2023)10.1002/cncr.34750

N/A

0.416DataRank · unranked

15 citations

Olga Martínez‐Sáez, Adrienne G. Waks, Alison Laws, Monica McGrath, Paolo Tarantino +11 more

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

European Urology Oncology(2024)10.1016/j.euo.2023.12.012

N/A

0.396DataRank · unranked

13 citations

Marta García de Herreros, Òscar Reig, Mercedes Marín‐Aguilera, Caterina Aversa, Laura Ferrer‐Mileo +21 more

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

Breast Cancer Research(2025)10.1186/s13058-025-01969-z

N/A

0.388DataRank · unranked

8 citations

Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Ulrike Nitz +25 more

ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27

Nature Communications(2025)10.1038/s41467-025-59184-5

N/A

0.373DataRank · unranked

11 citations

Yijie Wang, Lei Bao, Gonçalo Vale, Jeffrey G. McDonald, Yisheng Fang +9 more

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

Annals of Oncology(2024)10.1016/j.annonc.2024.12.010

N/A

0.208DataRank · unranked

3 citations

Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, Mattia Rediti +18 more

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf162

N/A

0DataRank · unranked

1 citations

Miguel Martín, Guillermo Villacampa, Marı́a del Monte-Millán, Rachel Yoder, Harsh B. Pathak +23 more

Figure S4 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

10.1158/1078-0432.22477253

N/A

0DataRank · unranked

0 citations

Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, María Vidal +8 more

Figure S1 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

10.1158/1078-0432.22477262

Top 100%

0DataRank

Top 100%0 citations

Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, María Vidal +8 more

Data from The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms

(2023)10.1158/0008-5472.c.6513133.v1

N/A

0DataRank · unranked

0 citations

Jing Zhang, Jung Hyun Lee, Jennifer M. Mason, Olga Karginova, Toshio F. Yoshimatsu +8 more

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

UNC Libraries(2020)10.17615/bgrr-9v25

N/A

0DataRank · unranked

0 citations

Anna Maria Storniolo, Vered Stearns, Vandana G. Abramson, Joel S. Parker, Catherine Van Poznak +19 more

MAP3K4/CBP-Regulated H2B Acetylation Controls Epithelial-Mesenchymal Transition in Trophoblast Stem Cells

UNC Libraries(2020)10.17615/awxx-pc97

N/A

0DataRank · unranked

0 citations

Leping Li, Piotr A. Mieczkowski, Weichun Huang, Aleix Prat, Alicia A. Midland +7 more

MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion

UNC Libraries(2020)10.17615/y54w-sk07

N/A

0DataRank · unranked

0 citations

Olufunmilayo I. Olopade, Kathy Yee, Geoffrey L. Greene, Simo Huang, Huiping Liu +9 more

Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation

UNC Libraries(2020)10.17615/xk87-3a74

N/A

0DataRank · unranked

0 citations

Aleix Prat, Piyush B. Gupta, Adam Skibinski, Charles M. Perou, Theresa A. Proia +7 more

MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11

UNC Libraries(2020)10.17615/bhpk-5y17

N/A

0DataRank · unranked

0 citations

Geoffrey L. Greene, Charles M. Perou, Yujia Wen, Seo Young Park, Ya-Fang Chang +14 more

The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms

Cancer Research(2021)10.1158/0008-5472.can-20-1959

N/A

0DataRank · unranked

16 citations

Jing Zhang, Jung‐Hyun Lee, Jennifer M. Mason, Olga Karginova, Toshio F. Yoshimatsu +8 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

International Journal of Infectious Diseases(2023)10.1016/j.ijid.2023.11.021

N/A

0DataRank · unranked

3 citations

Samuel Minkove, Isabel Ruíz-Camps, Simeón Eremiev, Gino M Dettorre, María Laura Fox +39 more

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3324

N/A

0DataRank · unranked

41 citations

Marta Palafox, Laia Monserrat, Fara Brasó‐Maristany, Andreu Òdena, Mònica Sánchez-Guixé +26 more

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Cancer(2024)10.1002/cncr.35323

N/A

0DataRank · unranked

20 citations

Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio Di Meglio +40 more

Aleix Prat

Indexed papers

Top data-sharing exemplar

Papers